Get the Stockscreener App
4.88
3.39%
0.16
Pepgen Inc stock is traded at $4.88, with a volume of 669.03K.
It is up +3.39% in the last 24 hours and down -23.75% over the past month.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.
See More
Previous Close:
$4.72
Open:
$4.77
24h Volume:
669.03K
Relative Volume:
0.94
Market Cap:
$337.28M
Revenue:
-
Net Income/Loss:
$-89.66M
P/E Ratio:
-2.0161
EPS:
-2.4205
Net Cash Flow:
$-81.90M
1W Performance:
-4.69%
1M Performance:
-23.75%
6M Performance:
-17.01%
1Y Performance:
+223.18%
1-Day Range:
$4.77
$5.10
1-Week Range:
$4.50
$5.10
52-Week Range:
$0.8801
$7.80
Pepgen Inc Stock (PEPG) Company Profile
Name
Pepgen Inc
Sector
Industry
Phone
703-456-8000
Address
1 MARINA PARK DRIVE, SUITE 900, BOSTON
Compare PEPG vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEPG
Pepgen Inc
|
4.88 | 326.22M | 0 | -89.66M | -81.90M | -2.4205 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Pepgen Inc Stock (PEPG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Initiated | Guggenheim | Buy |
| Dec-16-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-31-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-21-22 | Initiated | H.C. Wainwright | Buy |
Pepgen Inc Stock (PEPG) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc.PEPG - Bluefield Daily Telegraph
Value Recap: Why is PepGen Inc stock going downQuarterly Trade Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
If You Invested $1,000 in PepGen Inc (PEPG) - Stock Titan
Aug Patterns: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEAREarnings Miss & Technical Confirmation Trade Alerts - baoquankhu1.vn
PEPG Stock Price, Quote & Chart | PEPGEN INC (NASDAQ:PEPG) - ChartMill
PepGen, Inc. (NASDAQ:PEPG) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
PEPG SEC FilingsPepGen Inc 10-K, 10-Q, 8-K Forms - Stock Titan
COMMODORE CAPITAL LP Acquires Additional Shares in PepGen Inc - GuruFocus
How much upside is left in PepGen (PEPG)? Wall Street analysts think 75.44% - MSN
Boxer Capital Management LLC Invests $1.16 Million in PepGen, Inc. $PEPG - MarketBeat
Commodore Capital LP Invests $10.89 Million in PepGen, Inc. $PEPG - MarketBeat
FDA Places Partial Hold On PepGen's Myotonic Dystrophy Drug Trial - Sahm
PepGen shares slide 20% as FDA clinical hold overshadows earnings beat - MSN
Aug Volume: Is PepGen Inc stock a smart retirement pickPrice Action & Technical Pattern Recognition Alerts - baoquankhu1.vn
PepGen falls 20% despite earnings beat on FDA hold concerns By Investing.com - Investing.com Nigeria
Commodore Capital discloses 5.1% stake in PepGen (PEPG) - Stock Titan
PepGen CEO McArthur sells $32875 in shares By Investing.com - Investing.com Nigeria
FDA places partial clinical hold on PepGen’s DM1 trial - Investing.com Nigeria
PepGen unveils new research at MDA2026 poster session - Traders Union
Research Analysts Offer Predictions for PepGen Q1 Earnings - MarketBeat
Profit Review: Can PepGen Inc. stock double in the next year2026 Short Interest & Stepwise Trade Execution Plans - baoquankhu1.vn
Aug Momentum: What are the analyst revisions for NEOVIs PepGen Inc stock a good investment in YEARTrade Entry Summary & Short-Term Trading Alerts - baoquankhu1.vn
PepGen CEO McArthur sells $32875 in shares - Investing.com
Surprises Report: How does PepGen Inc correlate with NasdaqJuly 2025 PreEarnings & AI Driven Stock Reports - baoquankhu1.vn
PepGen (PEPG) CFO’s 2,084-share automatic sale covers RSU tax withholding - Stock Titan
PepGen (PEPG) CEO share sale covers RSU tax withholding obligations - Stock Titan
Grocery Outlet posts downbeat Q4 earnings, joins SES AI, PepGen and other big stocks moving lower in Thursday's pre-market session - MSN
Grocery Outlet Posts Downbeat Q4 Earnings, Joins SES AI, PepGen And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - wjfw.com
PepGen Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
FDA curtails Pepgen’s Freedom2 operate in DM1 - bioworld.com
PepGen Still On Track For PGN-EDODM1 Readouts Despite FDA Partial Hold - Citeline News & Insights
PepGen: Stock Slides On FDA Study HoldI'm Firmly On The Sidelines (NASDAQ:PEPG) - Seeking Alpha
PepGen muscular dystrophy drug gets ‘surprise’ hold from FDA - BioPharma Dive
Stifel reiterates Buy on PepGen stock amid partial clinical hold By Investing.com - Investing.com India
Stifel reiterates Buy on PepGen stock amid partial clinical hold - Investing.com Nigeria
PepGen: Clinical and Safety Uncertainties, FDA Partial Hold, and Valuation Gap Support Underperform Rating - TipRanks
PepGen stock slides on FDA partial hold (PEPG:NASDAQ) - Seeking Alpha
PepGen Updates EDO Platform and DM1 Program Outlook - TipRanks
PepGen falls 20% despite earnings beat on FDA hold concerns - Investing.com India
Why Is PepGen Stock Falling Thursday?PepGen (NASDAQ:PEPG) - Benzinga
FDA places partial clinical hold on PepGen’s DM1 trial By Investing.com - Investing.com Canada
US FDA puts partial clinical hold on PepGen’s muscle disease drug trial - 1470 & 100.3 WMBD
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights - PharmiWeb.com
PepGen Announces Regulatory Updates on FREEDOM2 - pharmiweb.com
Pepgen Inc Stock (PEPG) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):